Intellect Neurosciences Inc. (ILNS), a New York based biopharmaceutical company led by CEO Daniel Chain, was introduced to FNM Capital Funding with the development of a new breed of innovative “disease-modifying” therapeutic drugs designed to slow, arrest and ultimately prevent Alzheimer’s disease and other serious neurological disorders such as Parkinson’s disease. Furthermore, Daniel Chain was confident in the company’s ability to create and market a successful cure for these widespread diseases. Unfortunately, the company was highly leveraged and in desperate need of financing in order to seek FDA approval.
Intrigued by the impact of Intellect Neurosciences’ discovery, FNM Capital Funding developed a strategy that included the sale of one of Daniel Chain’s orphan drugs to ViroPharma, a multi-billion dollar pharmaceutical firm, which grossed $126 million in milestone payments. With the assistance of FNM Capital Funding, Intellect was able to pursue activities that resulted in the development of several drugs, which are now licensed and in advanced clinical trials by large pharmaceutical companies. FNM Capital Funding holds a percentage of the royalty patent on these trials.
Intellect holds an extremely valuable IP portfolio that is the envy of many, much larger pharmaceutical companies, which has established them as a truly pre-eminent international network among foremost industry leaders.
NEW YORK, Feb. 7, 2012 /PRNewswire/ — Intellect Neurosciences, Inc. (OTCBB:ILNS.PK – News), a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer’s and other neurological diseases today announced it has filed two United States and one international patent application regarding passive and active immunotherapy approaches targeting abnormal forms of tau protein that lead to death of nerve cells in Alzheimer’s disease.